Gri bio to present at the medinvest biotech & pharma investor conference

Live webcast on wednesday, april 3 rd at 10:10 am et la jolla, ca, march 28, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that marc hertz, phd, chief executive officer of gri bio, will present at the medinvest biotech & pharma investor conference being held in new york city, ny on wednesday, april 3, 2024 at 10:10 am et. in addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
GRI Ratings Summary
GRI Quant Ranking